Key facts
- Incendia Therapeutics’s last known valuation is $175.0M (Aug 2021).
- It has raised $78.3M; the latest was Later Stage VC ($13.3M) in Sep 2025.
- Notable investors include Alexandria Venture Investments, S32, Pfizer Ventures, Park West Asset Management, Aberdeen Investments (Scotland) — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Incendia Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Incendia Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Incendia Therapeutics
Operator of a novel therapeutics company intended to invent a class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The company designs a portfolio of drug candidates that interplay between cancer cells and their surrounding microenvironment, which is relevant in drug development to build barriers that shield the immune system from attacks, and one approach breaks these barriers to overcome recalcitrant cancers that are based on rigorous, ground-breaking research, enabling doctors to treat the right patients at the right time.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2019
- Employees
- 33
- Website
- incendiatx.com/
- Ownership
- Privately Held (backing)
Incendia Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Incendia Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Incendia Therapeutics in its N-PORT filings yet. We sweep new filings monthly.